The National Institute for Health and Care Excellence (NICE) published advice in January 2015 in relation to eculizumab (Soliris®) for the treatment of patients with atypical haemolytic uraemic syndrome (aHUS). At their meeting on 11 February 2015 AWMSG supported the adoption and implementation of this advice within NHS Wales (refer to the minutes of meetings). The Minister for Health and Social Services has subsequently agreed that the NICE HST advice for eculizumab (Soliris®) should be implemented within NHS Wales. Refer to HST1: Eculizumab for treating atypical haemolytic uraemic syndrome for full guidance on NICE recommendations, including any specific restrictions on the use of the technology.